I agree with this - you only have to look at Acadia and its development (or lack of) for Fragile X.
To be honest I’d actually suggest that if all indications stayed with Neuren that they’d all have a good chance of advancing, if that’s their plan.
I think it entirely possible for Neuren to undertake a phase 3 trial - but I’d think they’d license it sell from there - establishing global distribution would be difficult but not impossible.
I agree with this - you only have to look at Acadia and its...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.54 |
Change
-0.490(2.88%) |
Mkt cap ! $2.114B | |||
| Open | High | Low | Value | Volume |
| $16.94 | $17.02 | $16.38 | $10.33M | 620.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5061 | $16.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.62 | 1284 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |